‘A miracle': Snowboarder healing after scary accident
SIOUX FALLS, S.D. (KELO) — A Sioux Falls man is on the mend after a snowboarding accident nearly left him paralyzed.
His life is almost back to normal thanks to determination and unwavering support from his friends and family.
Nate Iveland started snowboarding after he moved to Sioux Falls in the 1980s.
'I remember being out at Great Bear, probably in 1986 or 1987, and I saw my first snowboard. It sounded like a big wheel coming down the road, and that's what I wanted to do, so I started snowboarding after that,' Nate Iveland said.
Giving voice to tongue cancer
He eventually started racing at Great Bear, which was what he was doing on January 29 when he suffered an injury that would completely alter his life for the next few months.
'My snowboard came out from underneath me, and I tried to save it. I just made it worse. I ended up sliding headfirst into a 4×4 off the side of the trail,' Nate Iveland said.
Iveland described it as a freak accident. It left him with fractures in his neck and back and unable to work.
'The doctor had taken the X-ray and he basically said I was lucky I didn't go into paralysis on the way there,' Nate Iveland said.
'It was a very scary time for our family,' Nate Iveland's mother, Jennifer Holsen said.
'It didn't really hit me until I was driving to work the next morning. Then, I just started bawling because all these things were just going through my head. It was just unbelievable,' Nate's wife, Lori Iveland said.
After having surgery, Iveland worked hard during his physical therapy.
'He's getting ready to go back to work in a week. It's a miracle, really. We consider it a miracle,' Holsen said.
It's not something Iveland could have done without support from his friends and family. Fundraisers like the one at The Smoked Culture in Sioux Falls Sunday and a GoFundMe that raised $20,000 have meant a lot to him.
'I can't tell you what all the love and support has meant to me and my family,' Nate Iveland said. 'It's been amazing.'
And he hopes to be back at Great Bear.
'I'm going to be snowboarding next winter. I don't know if I'm going to be racing again, but I'll probably go slow a little bit,' Nathan Iveland said.
Iveland says he'll be back to work on May 5th.
Details to the GoFundMe can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned -2.4%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has gained 10.1%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Hims & Hers Health is expected to post earnings of $0.17 per share, indicating a change of +183.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $0.73 points to a change of +170.4%. from the prior year. Over the last 30 days, this estimate has changed +0.6%. For the next fiscal year, the consensus earnings estimate of $1.04 indicates a change of +42.4% from what Hims & Hers Health is expected to report a year ago. Over the past month, the estimate has changed -0.6%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Hims & Hers Health. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Hims & Hers Health, the consensus sales estimate of $551.84 million for the current quarter points to a year-over-year change of +74.8%. The $2.34 billion and $2.9 billion estimates for the current and next fiscal years indicate changes of +58.5% and +23.8%, respectively. Hims & Hers Health reported revenues of $586.01 million in the last reported quarter, representing a year-over-year change of +110.7%. EPS of $0.2 for the same period compares with $0.05 a year ago. Compared to the Zacks Consensus Estimate of $538.09 million, the reported revenues represent a surprise of +8.9%. The EPS surprise was +66.67%. Over the last four quarters, Hims & Hers Health surpassed consensus EPS estimates two times. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Hims & Hers Health is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about Hims & Hers Health. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
TELO Rises on Promising Telomir-1 Preclinical Results
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
